Yes, hypertrophic cardiomyopathy is often genetic. In many families, it develops because a person inherits a disease-causing change in a gene involved in the structure or function of heart muscle. However, the full answer is more complicated than a simple yes-or-no checkbox.
Not everyone with hypertrophic cardiomyopathy, or HCM, has an identifiable genetic variant. Not everyone who inherits an HCM-related variant develops visible heart thickening. Even relatives carrying the same variant may have different symptoms, ages of onset, and medical risks. Genetics, in other words, provides important cluesbut it does not hand doctors a crystal ball with next Tuesday’s echocardiogram already loaded.
Understanding HCM inheritance can help patients make sense of genetic testing, alert relatives who may benefit from screening, and identify the condition before symptoms or complications appear. Here is what families should know.
The Quick Answer: Is Hypertrophic Cardiomyopathy Inherited?
Most classic cases of hypertrophic cardiomyopathy are considered heritable, meaning a person’s genes contribute significantly to the disease. HCM frequently follows an autosomal dominant inheritance pattern. This means that inheriting one disease-causing copy of an associated gene can increase the risk of developing the condition.
When a parent carries a confirmed pathogenic or likely pathogenic HCM variant, each biological child generally has a 50% chance of inheriting that specific variant. That probability resets with every pregnancy. Having one child who inherited the variant does not make the next child more or less likely to inherit it.
Importantly, a 50% chance of inheriting a variant is not necessarily a 50% prediction of developing severe disease. Some carriers never develop measurable hypertrophy, while others develop HCM during childhood, adolescence, adulthood, or later life. This difference is known as variable expression and incomplete penetrance.
What Is Hypertrophic Cardiomyopathy?
Hypertrophic cardiomyopathy is a disease in which part of the heart muscle becomes abnormally thick. The thickening commonly affects the left ventricle, particularly the wall separating the heart’s two lower chambers, called the interventricular septum.
Thicker does not automatically mean stronger. An excessively thick heart muscle may become stiff, making it harder for the ventricle to relax and fill with blood. In obstructive HCM, thickened tissue and abnormal movement of the mitral valve can partially block blood leaving the heart.
Possible consequences include:
- Shortness of breath, especially during physical activity
- Chest discomfort
- Fatigue or reduced exercise tolerance
- Palpitations or abnormal heart rhythms
- Dizziness or fainting
- Atrial fibrillation
- Heart failure symptoms
- An increased risk of sudden cardiac arrest in certain patients
Some people have no noticeable symptoms. Their HCM may be discovered after a heart murmur, an abnormal electrocardiogram, a sports evaluation, or screening prompted by a relative’s diagnosis.
How Do Genetic Changes Cause HCM?
Many HCM-associated genes provide instructions for proteins in the sarcomere, the microscopic machinery that allows heart muscle cells to contract and relax. A sarcomere is essentially the heart cell’s miniature engine room. When one of its components is built incorrectly, the muscle may contract inefficiently and gradually undergo abnormal thickening, disorganization, and scarring.
Two of the most frequently implicated genes are:
- MYBPC3, which provides instructions for cardiac myosin-binding protein C
- MYH7, which provides instructions for beta-myosin heavy chain
Other established HCM genes include TNNT2, TNNI3, TPM1, ACTC1, MYL2, and MYL3. Modern genetic panels may examine dozens of genes, although more genes do not automatically produce a clearer answer. Testing genes with weak or uncertain links to HCM can increase the chance of receiving confusing findings.
Not Every Thick Heart Is Sarcomeric HCM
Heart muscle thickening can also result from longstanding high blood pressure, aortic valve disease, intense athletic training, or other medical conditions. Certain genetic disorders, including Fabry disease, Danon disease, PRKAG2-related disease, and some metabolic or neuromuscular conditions, may imitate classic HCM. Cardiac amyloidosis can also produce increased ventricular wall thickness, particularly in older adults.
Doctors sometimes call these conditions HCM “phenocopies” because they resemble HCM on imaging but have different biological causes and may require different treatment. That is one reason diagnosis should combine medical history, physical examination, imaging, electrocardiography, family history, and carefully interpreted genetic testing.
Why Can HCM Look So Different Within One Family?
A family may share one HCM variant but not one identical medical story. One relative may develop mild thickening at age 60, another may experience symptoms in high school, and a third may carry the variant without showing HCM on current testing.
Several genetic concepts help explain this variation:
Incomplete Penetrance
Penetrance describes whether a person with a disease-associated variant develops detectable features of the condition. With incomplete penetrance, some carriers remain phenotype-negative, meaning their electrocardiogram and heart imaging do not yet show HCM.
Age-Related Expression
HCM may become visible at different ages. A normal echocardiogram at age 12 does not necessarily guarantee that a genetically at-risk person will have a normal echocardiogram at age 25 or 45. This is why some relatives need repeat cardiac evaluations rather than a single lifetime screening.
Variable Expressivity
Variable expressivity means that people carrying the same variant can have different degrees of heart thickening, obstruction, symptoms, rhythm problems, and complications. Additional genes, health conditions, lifestyle factors, age, and biological processes may influence how HCM appears.
New Genetic Variants
Occasionally, an HCM-related variant appears for the first time in an affected person rather than being inherited from either parent. This is called a de novo variant. Once present, however, that person may be able to pass the variant to their biological children.
Can You Have Genetic HCM Without a Family History?
Yes. An apparently negative family history does not rule out genetic hypertrophic cardiomyopathy.
Relatives may have mild or unrecognized disease. Someone may have died before being evaluated, been told they had an “enlarged heart,” or attributed breathlessness to aging. Families are also small, medical records may be incomplete, and some carriers never develop obvious symptoms.
A new variant may also have arisen in the first diagnosed family member. Adoption, limited knowledge of biological relatives, or relatives living in areas with limited access to cardiac care can further obscure the pattern.
Clinicians therefore look beyond the question, “Did anyone have HCM?” They may ask about unexplained fainting, sudden death at a young age, heart failure, implanted defibrillators, heart transplants, unexplained accidents, or relatives who died during exercise or sleep.
Who Should Consider Genetic Testing for HCM?
Genetic testing is generally most informative when it begins with a person who already has a clear clinical diagnosis of HCM. This person is often called the proband or index patient.
Testing the affected person first gives the laboratory the best chance of finding the specific variant responsible for the condition in that family. If a pathogenic or likely pathogenic variant is found, relatives can receive targeted testing for that exact variant. This step-by-step process is called cascade genetic testing.
Testing an unaffected relative before identifying a familial variant is often less useful. A negative broad panel in that relative would not reveal whether the family’s still-unknown cause was missed.
Genetic counseling before and after testing is strongly recommended. A cardiovascular genetic counselor can explain:
- What the test can and cannot determine
- Which family member should be tested first
- Possible results and their limitations
- Implications for children, siblings, and parents
- Privacy, insurance, and emotional considerations
- Reproductive options for people planning a family
What Do HCM Genetic Test Results Mean?
Pathogenic or Likely Pathogenic Variant
This result identifies a genetic change with strong evidence that it causes or contributes to HCM. It may explain the patient’s diagnosis and allows relatives to be tested specifically for the familial variant.
A positive result does not reliably predict exactly when symptoms will begin, how thick the heart will become, or whether a person will need a particular treatment.
Variant of Uncertain Significance
A variant of uncertain significance, commonly shortened to VUS, is a genetic change for which available evidence is insufficient to classify it as harmful or harmless. A VUS is not the same as a positive result.
It generally should not be used by itself to diagnose relatives or make major medical decisions. Laboratories may reclassify variants as scientific evidence improves, so patients should keep contact information updated with their genetics clinic.
Negative or Inconclusive Result
A negative test does not rule out HCM. The responsible variant may be in a gene not yet linked confidently to the disease, in a region the test did not detect well, or part of a more complex genetic pattern.
When someone already has clinically diagnosed HCM, their diagnosis remains valid even if no causative variant is found. Relatives may still need periodic electrocardiograms and cardiac imaging because there is no family-specific genetic test capable of clearing them.
How Are Family Members Screened?
First-degree relativesbiological parents, siblings, and childrenshould discuss HCM screening with a qualified clinician. Screening can begin at any age, with timing individualized according to the family’s history, symptoms, known variant, athletic participation, and preferences.
Clinical screening usually includes:
- A review of symptoms and family history
- A physical examination
- An electrocardiogram, or ECG/EKG
- An echocardiogram
Some people may also need cardiac magnetic resonance imaging, exercise testing, or ambulatory rhythm monitoring.
For relatives who remain at risk, contemporary U.S. guidance commonly recommends repeat screening every one to two years in growing children and adolescents and every three to five years in adults. Evaluations may be more frequent when symptoms develop, a family has early-onset disease, or a clinician identifies concerning findings.
When a familial pathogenic variant is known, a relative who tests negative for that exact variant can often be released from ongoing HCM surveillance for that family-specific genetic risk, unless clinical findings or another medical issue suggest otherwise.
Does Genetic Testing Replace an Echocardiogram?
No. Genetic and clinical testing answer different questions.
A genetic test asks whether a person carries a recognized DNA variant associated with HCM. An echocardiogram asks whether the heart currently shows structural features of disease. An ECG evaluates electrical activity. Cardiac MRI can provide more detailed information about anatomy and tissue characteristics.
A person can be genotype-positive but phenotype-negative, meaning the variant is present but current cardiac testing is normal. The reverse is also possible: someone can have definite clinical HCM while genetic testing does not identify a causative variant.
Can Genetic HCM Be Prevented?
A person cannot currently rewrite an inherited HCM variant through diet, supplements, or heroic consumption of kale. However, early identification can reduce uncertainty and improve medical planning.
Monitoring can detect changes before symptoms become severe. Treatment may include medication, rhythm management, an implantable cardioverter-defibrillator for selected high-risk patients, septal reduction procedures for significant obstruction, or other individualized therapies.
People with HCM should receive personalized advice about exercise rather than assuming all activity is forbidden. Modern guidance emphasizes shared decision-making based on symptoms, cardiac findings, rhythm history, treatment, and the type and intensity of activity.
People planning children may discuss prenatal testing, egg or sperm donation, adoption, natural conception with postnatal testing, or in vitro fertilization with preimplantation genetic testing when a familial pathogenic variant is known. These are personal choices, not mandatory medical assignments.
Symptoms That Deserve Prompt Medical Attention
People with known HCM, an HCM-associated variant, or a strong family history should report new symptoms to their healthcare team. These may include fainting, near-fainting, exercise-related chest discomfort, worsening shortness of breath, sustained palpitations, or a sudden decline in exercise ability.
Call 911 for collapse, severe or persistent chest pain, marked breathing difficulty, or signs of cardiac arrest. A family history of sudden unexplained death should also be discussed with a cardiologist rather than stored in the family archive beside old recipes and mysterious unlabeled photographs.
Common Questions About HCM Genetics
Can HCM Skip a Generation?
It may appear to skip a generation because a carrier has no symptoms or detectable thickening. The variant can still be passed on, and another relative may develop more obvious disease.
Can Either Parent Pass Down HCM?
Yes. Autosomal dominant HCM variants can be inherited from a mother or father. The likelihood of transmission is not determined by the child’s sex.
Does a Positive Genetic Test Mean HCM Is Inevitable?
No. It confirms increased genetic susceptibility but does not guarantee detectable disease or predict severity. Ongoing screening is used to determine whether the heart develops HCM features.
Does a Negative Test Mean My Children Are Safe?
Not always. When the affected patient’s test is negative or inconclusive, the family may still have inherited HCM without an identifiable variant. Clinical screening may remain necessary.
Should Healthy Children Be Tested?
Testing may be appropriate when a pathogenic familial variant has been identified because results can guide cardiac surveillance. Decisions should involve the child’s cardiology and genetics teams and consider age, family history, emotional readiness, and how the result would change care.
Experiences Families May Have During the HCM Genetic Journey
The following examples are composites designed to reflect common experiences. They do not describe specific patients and should not replace individualized medical advice.
The Diagnosis That Seems to Arrive From Nowhere
For some people, the genetic journey begins with symptoms. A recreational runner notices unusual breathlessness. A college student faints during practice. A parent mentions chest pressure that appears only when climbing hills. For others, the diagnosis begins with an incidental murmur or abnormal ECG during a routine appointment.
The first reaction may be disbelief: “But no one in our family has a heart condition.” After a more detailed history, forgotten clues sometimes emerge. A grandfather died unexpectedly at 46. An aunt was told she had an unusually thick heart. A cousin received a defibrillator but never explained why.
Learning that these events might be connected can feel clarifying and unsettling at the same time. Families may feel relief that there is an explanation, followed immediately by concern about children and siblings.
Telling Relatives Can Be the Hardest Part
Genetic results are personal, but they are also relevant to biological relatives. That creates an unusual communication challenge. One patient may call every sibling the same evening. Another may postpone the conversation because a relative is pregnant, stressed, uninsured, or famously skilled at avoiding medical appointments.
A genetics clinic can often provide a family letter explaining the finding, who may be at risk, and what screening to request. This removes some pressure from the patient, who should not be expected to become the family’s unpaid cardiologist, geneticist, therapist, and scheduling department.
Relatives may react differently. One wants testing tomorrow. Another prefers clinical screening without genetic testing. A third needs time to process the information. These responses do not necessarily reflect how much a person cares; they often reflect different ways of managing uncertainty.
Waiting for Results Can Feel Longer Than It Is
The laboratory wait may produce a parade of questions. Will the result explain everything? Will it affect the children? What happens if it is uncertain? Some people repeatedly check the patient portal as though refreshing the page might personally encourage the DNA sequencer.
Pretest counseling can make this period easier by preparing the patient for all possible outcomes. A clear positive result can guide family testing, but a negative result or VUS is common enough that it should never be treated as a laboratory failure or personal defeat.
Living With a Positive Variant and a Normal Heart
A genotype-positive, phenotype-negative person may feel caught between “healthy” and “at risk.” Current testing may be reassuring, yet periodic follow-up remains important. Children and young adults may wonder whether sports, careers, pregnancy, or travel plans must change.
In many cases, the answer is not a blanket prohibition. The care team reviews the individual’s imaging, rhythm tests, symptoms, family history, and goals. A personalized plan can replace vague fear with specific actions: attend scheduled screening, report warning symptoms, stay hydrated as advised, and discuss major exercise changes with a knowledgeable clinician.
Finding a New Family Routine
Over time, HCM screening may become another recurring family taskless exciting than a reunion but considerably more useful. One sibling schedules an echocardiogram. A teenager attends a pediatric cardiology appointment. Parents update relatives when a variant is reclassified.
The emotional burden often becomes more manageable once responsibilities are divided. The patient shares accurate information, relatives make their own testing decisions, and specialists interpret the results. Support groups and HCM centers can also help families realize they are not navigating a uniquely strange genetic maze.
For many people, genetic knowledge ultimately provides more control rather than less. It cannot predict every outcome, but it can identify who needs attention, spare some relatives from unnecessary surveillance, and turn a mysterious family pattern into a practical healthcare plan.
Conclusion
Hypertrophic cardiomyopathy is frequently genetic, most often involving inherited changes in genes that help heart muscle contract. A confirmed pathogenic variant is commonly passed in an autosomal dominant pattern, giving each biological child of a carrier a 50% chance of inheriting that variant.
Inheritance does not determine destiny. Some carriers never develop measurable HCM, while affected relatives may differ greatly in age of onset and severity. A negative genetic test also cannot exclude clinically diagnosed HCM or inherited risk when the family’s causative variant remains unknown.
The most useful approach combines genetic counseling, testing of an affected family member, targeted cascade testing when possible, and appropriate ECG and heart-imaging surveillance for relatives. Anyone with HCM or a family history of unexplained cardiac disease should discuss a personalized screening strategy with a cardiologist or cardiovascular genetics team.
Medical note: This article is intended for general education and is not a diagnosis or individualized treatment plan. Seek professional medical care for personal questions, and call 911 for collapse, severe chest pain, signs of cardiac arrest, or serious breathing difficulty.
